探索下一代抗体-药物联合体的研究
Kyoji Tsuchikama1, Yasuaki Anami2, Summer Y Y Ha2
1Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA. kyoji.tsuchikama@uth.tmc.edu.
Nature reviews. Clinical oncology
|January 9, 2024
概括
创新的抗体-药物合物 (ADC) 格式,如双特异性和试验体药物合物,可增强瘤向性并对抗药物耐药性. 在ADC组件和设计方面的进步对于有效的癌症治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 抗体-药物合物 (ADC) 是一种关键的癌症治疗方法,可以选择性地将细胞毒药物输送到瘤中.
- 药物耐药性,瘤异质性和不良反应等临床挑战限制了目前的ADC疗效.
- 需要新的ADC设计来克服这些局限性并改善患者的治疗结果.
研究的目的:
- 审查新兴的抗体-药物联合体 (ADC) 格式及其在癌症治疗中应对临床挑战的潜力.
- 突出ADC组件 (抗体,有效载荷,链接器,结合化学) 的进展及其对新型ADC开发的影响.
- 强调患者分层和生物标志物识别对于新兴ADC疗法的重要性.
主要方法:
- 关于抗体-药物联合体 (ADC) 进展的当前文献的综述.
- 分析新兴的ADC格式,包括双特异性,试验体药物联合体,免疫刺激,蛋白质降解和双药ADC.
- 讨论ADC组件的工程策略及其临床影响.
主要成果:
- 几种新的ADC格式 (双特异性,试验体药物联合体,免疫刺激,蛋白质降解剂,双药物) 显示出独特的能力.
- 实体药物联结剂增强瘤特异性;双特异性和双药物ADC改善抗抗性和异质性的活性.
- 免疫刺激和蛋白质降解ADC为多模式癌症治疗提供了不同的机制.
结论:
- 新兴的ADC格式对克服目前耐火性癌症治疗的局限性有很大的希望.
- 在ADC设计中不断创新,加上患者分层和生物标记物识别,对于最大限度地提高治疗效益至关重要.
- 在ADC组件和结合化学方面的进步正在为更有效,更安全的癌症疗法铺平道路.
更多相关视频
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
6.9K
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
相关概念视频
01:26Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
01:10Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
01:25Antibody Structure and Classes
914
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
914
01:14Phase II Conjugation Reactions: Overview
207
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
207